iTeos to Participate in Upcoming Investor Conferences in September
September 08 2020 - 4:05PM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today announced that management will
participate in two upcoming virtual investor conferences in
September.
Citi’s 15th Annual BioPharma Virtual
ConferenceDate: Wednesday, September 9 –
Thursday, September 10, 2020
H.C. Wainwright 22nd Annual Global Investment
ConferenceDate: Tuesday, September 15,
2020Presentation Time: 5:00 p.m. ET
A live audio webcast of the H.C. Wainwright presentation will be
available on the News and Events section of iTeos’ investor website
at https://investors.iteostherapeutics.com/. A replay of the
webcast will be available for 30 days following the
presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of the tumor
microenvironment and immunosuppressive pathways to design novel
product candidates with an aim to improve the clinical benefit of
oncology therapies. The innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed to build on prior learnings in the field to have
differentiated pharmacological and clinical profiles. The most
advanced product candidate, EOS-850, is designed as a highly
selective small molecule antagonist of the adenosine A2a receptor,
in the adenosine triphosphate adenosine pathway, a key driver of
immunosuppression in the tumor microenvironment across a broad
range of tumors. EOS-850 is being investigated in an open-label
Phase 1/2a clinical trial in adult patients with advanced solid
tumors and encouraging preliminary single-agent activity were
observed in the dose escalation portion of the trial. The lead
antibody product candidate, EOS-448, is an antagonist of TIGIT, or
T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that
has a role in both inhibitory and stimulatory pathways in the
immune system. EOS-448 was also designed to engage the Fc gamma
receptor, or FcγR, to promote antibody-dependent cellular
cytotoxicity, or ADCC, activity, including the elimination of
tumor-infiltrating regulatory T cells, or Tregs. An open-label
Phase 1/2a clinical trial of EOS-448 was recently initiated in
adult patients with advanced solid tumors. Therapeutics is
headquartered in Cambridge, MA with a research center in Gosselies,
Belgium.
For further information, please contact:
Media Contacts:Amber Fennell, Paul
KidwellConsilium Strategic Communications+44 203 709
5700iteos@consilium-comms.com
Investor Contacts:Sarah McCabe, Zofia MitaStern
Investor Relations, Inc.+ 1 212 362 1200iTeos@sternir.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2023 to Sep 2024